Novo Nordisk is investing more than $1 billion in a new production facility in Denmark. Elsewhere, drugs from Neurocrine ...

The $16.5 billion take-private deal can now be completed, and along with it Novo Nordisk’s related acquisition of three ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

After clearing all regulatory hurdles associated with its proposed buyout of CDMO Catalent, Novo Holdings is nearly ready to ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge ...

The latest update is out from Novo Nordisk ( (NVO) ).

Danish pharmaceutical firm Novo Nordisk A/S (NYSE:NVO) announced plans to invest approximately $1.20 billion (8.5 billion ...

Novo’s latest investment comes just days after the U.S. FTC greenlit the highly contentious acquisition of Catalent, which ...

Novo Nordisk is investing $1.2 billion in a rare disease drugs facility in Denmark, weight-loss drugs surge American ...

Now that they’ve received the go-signal from both U.S. and EU anti-trust regulators, Novo Holdings and Catalent expect to ...

Find insight on Novo Holdings, Malaysian glove sector and more in the latest Market Talks covering health care.